Drugs / EVICEL Fibrin Sealant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01589822 | Jun 2012 → Jan 2014 | digestive system disorder | Ethicon, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02457546 | Jul 2015 → Sep 2017 | cerebrospinal fluid leak | Ethicon, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVICEL Fibrin Sealant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01589822 ↗ |
| Modality | Protein / enzyme biologic | “EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen” NCT01589822 ↗ |